NIH ends fetal tissue research—again

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NIH will no longer fund scientific research that uses human fetal tissue from elective abortions, a practice that has contributed to the study of cancer, the development of vaccines, and the treatment of other diseases. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

UCLA researchers have received a grant worth up to $7 million over five years from the National Institute of Allergy and Infectious Diseases to launch a first-in-human clinical trial evaluating whether drugs already used to treat autoimmune diseases can prevent or reverse immune checkpoint inhibitor-induced type 1 diabetes, a rare but often permanent complication of cancer immunotherapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login